User login
Key clinical point: Patients with relapsing-remitting MS gain comparable benefits from cladribine therapy, regardless of age.
Major finding: The annual rate of qualifying relapses was 0.14 for treated patients older than 45 years and 0.15 for treated patients aged 45 or younger.
Study details: A post hoc analysis of data from the CLARITY and CLARITY extension studies, which included 870 patients.
Disclosures: Merck KGaA, which manufactures and markets cladribine, supported the study. Several of the investigators have received speaker honoraria, consulting fees, or other funding from Merck KGaA.
Citation: REPORTING FROM CMSC 2019
Key clinical point: Patients with relapsing-remitting MS gain comparable benefits from cladribine therapy, regardless of age.
Major finding: The annual rate of qualifying relapses was 0.14 for treated patients older than 45 years and 0.15 for treated patients aged 45 or younger.
Study details: A post hoc analysis of data from the CLARITY and CLARITY extension studies, which included 870 patients.
Disclosures: Merck KGaA, which manufactures and markets cladribine, supported the study. Several of the investigators have received speaker honoraria, consulting fees, or other funding from Merck KGaA.
Citation: REPORTING FROM CMSC 2019
Key clinical point: Patients with relapsing-remitting MS gain comparable benefits from cladribine therapy, regardless of age.
Major finding: The annual rate of qualifying relapses was 0.14 for treated patients older than 45 years and 0.15 for treated patients aged 45 or younger.
Study details: A post hoc analysis of data from the CLARITY and CLARITY extension studies, which included 870 patients.
Disclosures: Merck KGaA, which manufactures and markets cladribine, supported the study. Several of the investigators have received speaker honoraria, consulting fees, or other funding from Merck KGaA.
Citation: REPORTING FROM CMSC 2019